Compare Invesco Ltd. (IVZ) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Invesco Ltd. trades at $27.87 (market cap $12.33B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $37.8 (market cap $63.89B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 5.2× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (3.08%). Which is the better fit depends on your goals.
| IVZ | RELX | |
|---|---|---|
Market Cap | $12.33B | $63.89B |
Volume | 4,127,288 | 2,760,502 |
Sector | Financials | Industrials |
52-Week High | $33.31 | $46.80 |
52-Week Low | $22.44 | $27.73 |
Typical Hold Time | 77 Days | — |
Enterprise Value | $22.50B | $75.40B |
Dividend Yield | 3.08% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $28.92, down 1.16% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $6.38B in 2025 but negative net margins of -0.93%. Analyst consensus remains cautiously optimistic with a $33.17 price target and no sell ratings, while technical indicators suggest near-term pressure with support at $28.
Investment outlook balances strong asset growth momentum (AUM up 4.7% to $2.56T in August 2026) against profitability challenges. Key opportunities include dividend yield and ETF expansion, while risks center on margin pressure and market volatility. The stock presents value potential if operational improvements materialize.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →
